Human pluripotent stem cells (hPSC) have the potential to become important tools for the establishment of new models for in vitro drug testing of, for example, toxicity and pharmacological effects. Late-stage attrition in the pharmaceutical industry is to a large extent caused by selection of drug candidates using nonpredictive preclinical models that are not clinically relevant. The current hepatic in vivo and in vitro models show clear limitations, especially for studies of chronic hepatotoxicity. For these reasons, we evaluated the potential of using hPSC-derived hepatocytes for long-term exposure to toxic drugs. The differentiated hepatocytes were incubated with hepatotoxic compounds for up to 14 days, using a repeated-dose approach. The hPSC-derived hepatocytes became more sensitive to the toxic compounds after extended exposures and, in addition to conventional cytotoxicity, evidence of phospholipidosis and steatosis was also observed in the cells. This is, to the best of our knowledge, the first report of a longterm toxicity study using hPSC-derived hepatocytes, and the observations support further development and validation of hPSCbased toxicity models for evaluating novel drugs, chemicals, and cosmetics.
Introduction
The liver is one of the most affected organs involved in drug-related toxicity. More than 30% of the terminations of drug development programs are caused by adverse effects in the liver, and liver toxicity represents almost 20% of the safety-related, postmarket withdrawals (Ballet, 1997) .
The pharmaceutical industry currently lacks relevant in vitro models that can predict human liver toxicity early in the drug development process. The gold standard of in vitro models for hepatotoxicity is primary human hepatocyte (PHH) cultures, which is considered the most relevant model for human liver toxicology applications currently available (Guillouzo and Guguen-Guillouzo, 2008) . However, the low availability, large donor variation, and the rapid loss of metabolic activity following in vitro culture limit their usefulness, in particular for detecting chronic toxicity (Guguen- . One alternative to the PHH that has emerged during recent years is the human hepatocellular carcinoma cell line HepaRG, a bipotent progenitor cell line with the ability to differentiate into hepatocyte and biliary lineages (Gripon et al., 2002) . The differentiated hepatocyte-like cells retain many of the functions of PHH, and the potential to use HepaRG in metabolism and toxicity studies has been reported (Aninat et al., 2006; Kanebratt and Andersson, 2008; Antherieu et al., 2010; Andersson et al., 2012) . However, further evaluation of HepaRG as a toxicity model is needed, because a direct comparison between HepaRG, PHH, and human liver hepatocellular carcinoma cell line (HepG2) indicated a low sensitivity for detection of hepatotoxic drugs in HepaRG (Gerets et al., 2012) . Another extensively used hepatic cell model is the HepG2 tumor cell line (Sassa et al., 1987) . Despite the frequent usage of these cells, the resemblance to PHH is low and the fact that these cells proliferate in culture makes them impractical for long-term studies (Xu et al., 2004; Gerets et al., 2009; Gerets et al., 2012) .
Other novel in vitro models have been evaluated for their usefulness in studies of long-term drug exposure. Micro-patterned cocultures of PHH and murine stromal fibroblasts displayed a functional stability to enable a 9-day repeated-dose exposure with 65.7% sensitivity to detect drug-induced liver injury (Khetani et al., 2013) . There are also reports of a canine coculture model of hepatocytes and nonparenchymal stromal cells with metabolic capacities maintained for up to 2 weeks and a superiority for the classification of drug-induced liver injury compounds compared with HepG2 and PHH during 5-day compound exposure (Atienzar et al., 2014) . However, prediction of liver toxicity using different cell models needs further investigation because sensitivity and specificity vary, a result that could be due to time of exposure, selection of investigated substances, and the specific cell type used (Gerets et al., 2012) .
Human pluripotent stem cells (hPSC) offer a new approach for generating cells for in vitro models. The ability of unlimited propagation and the potential to differentiate into all cell types in the 
at ASPET Journals on October 29, 2017 dmd.aspetjournals.org human body make hPSC very attractive (Thomson et al., 1998; Takahashi et al., 2007) . Protocols to differentiate human embryonic stem cells and human induced pluripotent stem cells into hepatocytes have improved immensely in recent years, and now hepatocyte cultures with high purity and many characteristics of functional hepatocytes can be obtained from hPSC (Brolen et al., 2010; Si-Tayeb et al., 2010; Touboul et al., 2010; Yildirimman et al., 2011; Hannan et al., 2013; Ulvestad et al., 2013; Szkolnicka et al., 2014) . The fact that these cells can be derived in a robust and reproducible fashion from a well-characterized source makes them very attractive as a toxicity assessment model. In this study, we have evaluated the potential of using human induced pluripotent stem cell-derived hepatocytes to study hepatotoxicity in response to chronic drug exposure. Earlier studies have shown that in many cases repeated dosing and exposure for 2 weeks are necessary to be able to detect human toxicity of drugs (Olson et al., 2000; Roberts et al., 2014) . The hepatocytes used in our study, human induced pluripotent stem cell-derived hepatocytes (hiPS-HEP), were exposed to relevant concentrations of hepatotoxic compounds for 2, 7, and 14 days of repeated dosing. The cell morphology was monitored during the entire time period, and the cell viability, as well as the induction of steatosis and phospholipidosis, was assessed at each time point. Importantly, the data show that the hiPS-HEP model is stable enough to enable at least a 2-week study of drug exposure and that it is specific enough to assess hepatotoxic responses on a mechanistic level.
Materials and Methods
Cell Culture. hiPS-HEP were obtained from Cellectis AB (Gothenburg, Sweden) and cultured according to the instructions from the manufacturer. The cells were maintained in 96-well plates, and medium was replaced every second day during the compound incubation. The human hepatocellular carcinoma cell line HepG2 was used as a control cell model. The HepG2 cells were purchased from American Type Culture Collection and cultured in Dulbecco's modified Eagle's medium (high glucose, GlutaMAX supplement, pyruvate; Gibco/Life Technologies, Stockholm, Sweden) supplemented with 10% heatinactivated fetal bovine serum (Gibco/Life Technologies), 1% penicillinstreptomycin (Gibco/Life Technologies), and 1% nonessential amino acids (Gibco/ Life Technologies).
Materials. Four model compounds known to cause hepatotoxicity were used in this study. Amiodarone [2-butyl-3-benzofuranyl-4-[2-(diethylamino)ethoxy]-3,5-diiodophenyl ketone hydrochloride], aflatoxin B1 [(6aR,9aS)-4-methoxy-2,3,6a,9a-tetrahydrocyclopenta[c]furo [39,29:4,5] furo[2,3-h]chromene-1,11-dione], and troglitazone [5-[[4-[(3,4- 
-hydroxycarbamimidoyl]phenyl} methyl)carbamoyl]azetidin-1-yl]-2-oxoethyl]amino}acetate] was provided by AstraZeneca, R&D (Mölndal, Sweden). All compounds were purchased as powder and dissolved in dimethyl sulfoxide (DMSO) to a stock solution concentration 250Â higher than the top assay concentration (see Table 1 for details on compounds). EZ4U cell proliferation and cytotoxicity assay was purchased from Biomedica/Biotech-IgG (Copenhagen, Denmark). The fluorescent probes for the imaging analysis, Hoechst 33342, HCS LipidTOX green neutral lipids, and HCS LipidTOX red phospholipidosis were acquired from Life Technologies, Invitrogen (Stockholm, Sweden).
Dose-Response Study and Viability Testing. The hiPS-HEP were exposed to various concentrations of the compounds for three different time points as follows: one single-dose exposure for 2 days and repeated-dose exposures for 7 (three repeated doses) and 14 days (six repeated doses), respectively. Each compound was half-log diluted in DMSO from a DMSO stock solution and then further diluted in a two-step procedure: first 25Â dilutions in cell culture medium followed by a 10Â dilution in the cell culture plates. The final concentration of DMSO was 0.4%. Every sample was assayed in triplicate wells for each time point. After incubation with the compounds, the cell viability was assessed using the EZ4U cell proliferation and cytotoxicity assay according to the instructions from the provider. The absorbance at 492 nm was measured in a FLUOstar Omega plate reader (BMG LABTECH, Ortenberg, Germany), and the samples were blank-corrected and normalized to vehicle control.
Dose-response curves were plotted as percentage of vehicle control using GraphPad Prism 4 (GraphPad Software Inc., La Jolla, CA), and effective concentrations at 10 % mortality (EC 10 ) were generated using nonlinear sigmoidal dose-response regression. Because the values were normalized to the vehicle control, constraints of TOP = 100 and BOTTOM = 0 were included in the regression setup.
Assessment of Steatosis and Phospholipidosis. To assess the induction of steatosis and phospholipidosis following compound exposure, cells stained with fluorescent probes for neutral lipids and phospholipids were measured using quantitative image analysis. To avoid nonspecific general cytotoxic effects, the concentration used for each compound was the EC 10 from the 14-day dose-response study. The following concentrations were used: amiodarone, 2.5 mM; aflatoxin B1, 0.1 mM; troglitazone, 40 mM; ximelagatran, 10 mM. At the last medium change, 48 hours before the termination of the experiment, the HCS LipidTOX Red Phospholipidosis substrate was added to the cells together with the compounds. At termination of the study, the cell viability was assessed using the EZ4U kit, as described above, and the cells were fixed in 4% formaldehyde for 30 minutes. After subsequent washing steps with Dulbecco's phosphate-buffered saline + / + , Hoechst stain, at a final concentration of 10 mg/ml (1000-fold dilution), was added to the wells and the cells were incubated at room temperature for 20 minutes. Alternatively, to assess the steatosis, the HCS LipidTOX Green Neutral Lipid was diluted 1000-fold in Dulbecco's phosphate-buffered saline + / + and added to the cells. The cells were kept at room temperature for a minimum of 30 minutes prior to storage at +4°C until further analysis.
Automated Imaging and Analysis. Cell cultures in 96-well imaging plates (BD Falcon, Stockholm, Sweden) were imaged using an automated robotic microscope (ImageXpress Micro, from Molecular Devices, Sunnyvale, CA) fitted with a 10Â Nikon plan fluor objective (NA 0.3). Image acquisition and processing were performed using MetaXpress software (version 5.1, from Molecular Devices). To accommodate the variable thickness of these cultures and to facilitate image analysis, focal stacks were taken for each wavelength and processed to produce single images containing only in-focus pixels. Cellular nuclei were then identified in each image and classified as positive for steatosis and phospholipidosis based on multiple thresholds for lipid morphology, staining intensity, and the area stained for each cell. Data are reported as percentage of positive cells in which the total population was defined by the nuclear staining.
Statistical Analysis. To test whether the dose-response curves significantly differed at each time point, an F-test was performed using GraphPad Prism 4 (GraphPad Software Inc.). A P value # 0.05 was considered statistically significant.
Results
hiPS-HEP Characteristics. The drug metabolism and transporter functions in the hiPS-HEP have previously been characterized in detail and compared with cryopreserved PHH cultured for 4 and 48 hours (Ulvestad et al., 2013) . Notably, the hiPS-HEP show stable gene and protein expression as well as functional activity of transporters and cytochrome P450 (P450) during in vitro culture. In the present investigation, we focused on prediction of hepatotoxicity using hiPS-HEP in long-term cultures. At the start of the experiments, the hiPS-HEP formed a highly homogeneous (.90%) monolayer of hepatocytes with a morphology resembling PHH. The cells displayed typical polygonal shape, clear cell-cell borders, and prominent light nuclei surrounded by dark cytoplasm (Fig. 1A) . The cells expressed several hepatocyte-associated markers, such as cytokeratin 18 and hepatocyte nuclear factor 4a, and showed ability to store glycogen, as illustrated in Fig. 1, B-D. Notably, the hiPS-HEP exhibited some P450 enzyme activity at levels comparable to that of PHH cultured for 48 hours. Specifically, the hiPS-HEP showed ;30% of CYP1A and more than fourfold higher CYP3A activity (Ulvestad et al., 2013) . The cells expressed these characteristics stably for more than 2 weeks, without any sign of proliferation, which allowed for the setup of an extensive repeated dose testing.
hiPS-HEP Sensitivity to Hepatotoxic Compounds. As shown in Fig. 2 , the initial dose-response study demonstrated that the hiPS-HEP were sensitive to several of the compounds tested, indicated by the drop in viability at increased concentration of amiodarone, aflatoxin B1, and troglitazone. For troglitazone, the viability dropped from approximately 100% to near 0% within a narrow concentration range. The hiPS-HEP responded strongly to amiodarone and aflatoxin B1 in a time-dependent manner. A significant (P , 0.001) shift of the viability curve was observed for 7-day (Fig. 2, blue ) and 14-day exposure (Fig. 2, black) compared with the 2-day exposure (Fig. 2, red) . This indicates that the cells are more sensitive over long-term, repeated-dose exposures compared with shortterm single-dose exposures. The hiPS-HEP were nonresponsive to ximelagatran. Comparable levels of sensitivity were observed for HepG2 and hiPS-HEP cells when exposed to the compounds for 48 hours (Fig. 2, green) , whereas it was not possible to use HepG2 for the long-term treatment due to the high extent of cell proliferation.
Induction of Steatosis and Phospholipidosis. To evaluate whether the hiPS-HEP responded to the compounds in a hepatocyte-specific way, we assessed the compounds' ability to induce steatosis and phospholipidosis. For these experiments, a subcytotoxic concentration (Do and Choi, 2007) CYP3A4, CYP1A2 (Guengerich et al., 1996) Troglitazone 125 Idiosyncratic hepatotoxic, impaired mitochondria function (Jaeschke, 2007) CYP3A (Kassahun et al., 2001) Ximelagatran 400 Unknown hepatotoxic mechanism, connected to raised aminotransferase levels (Lee et al., 2005) None of the major P450s are involved in the metabolism (Bredberg et al., 2003; Clement and Lopian, 2003) Amiodarone induced phopholipidosis in hiPS-HEP ( Fig. 3B) after 7and 14-day exposure. Representative images of the amiodarone-induced phospholipidosis, in comparison with the control, are shown in Fig. 3D . Steatosis was detected in cells dosed with troglitazone ( Fig. 3C ) for 2 days, and with increasing number of positively stained cells after 7-and 14-day exposures.
Discussion
There is a great need in the pharmaceutical industry today for more predictive cell-based models for toxicity assessment. In this study, we demonstrate the potential of using hPSC-derived hepatocytes as an in vitro model for long-term hepatotoxicity. The hiPS-HEP represent a robust and reproducible population of cells with many hepatic characteristics that can be maintained for at least 2 weeks in culture, thus enabling a repeated-dose chronic exposure to hepatotoxic compounds. The hepatocytes respond to the compounds in a dose-dependent manner and show increasing sensitivity to amiodarone and aflatoxin B1 during long-term exposure. The induction of steatosis and phospholipidosis can also be assessed to evaluate the hepatocyte-specific toxic response after compound exposure. The hiPS-HEP display a clear phospholipidosis when exposed to amiodarone, and the effect increases during the exposure time period. Troglitazone induces steatosis in the cells in a similar manner, with increasing number of positive cells with time.
The expression and activity of several important metabolizing P450 enzymes and transporter proteins in hiPS-HEP have previously been investigated (Ulvestad et al., 2013) . Those studies revealed a high activity of CYP3A in the cells, even higher than in PHH cultured for 48 hours, and importantly, the high activity was stable over time. CYP3A is involved in the metabolism of many drugs and is therefore of great importance in toxicity and metabolism studies (Guengerich, 1999) . The high CYP3A expression in the hiPS-HEP corresponds well to their sensitivity to the hepatotoxic compounds used in the present study. The hiPS-HEP respond strongly to amiodarone and alfatoxin B1, both of which are highly dependent on CYP3A activity to generate toxic metabolites (Guengerich et al., 1996; Elsherbiny et al., 2008) . The viability dose-response curves display a significant shift toward lower concentrations during the 7and 14-day exposure. The other two compounds tested in this study, troglitazone and ximelagatran, behave differently. The hiPS-HEP are sensitive to troglitazone at higher concentrations, and the viability drops from nearly 100% to close to 0% from one concentration to the next, in the interval of 12.5 mM and 125 mM, making the calculation of the EC 10 values difficult. Nevertheless, the results indicate that the toxicity increases with longer exposure times. We also included ximelagatran, a direct thrombin inhibitor that was withdrawn from the market because of elevated liver enzymes (alanine aminotransferase levels) during long-term clinical trials (Lee et al., 2005) . Ximelagatran has been investigated in several preclinical studies without showing an effect on cellular functions, even at concentrations much higher than the plasma concentration during therapeutic dosing (Kenne et al., 2008) . The hiPS-HEP model, despite the possibility of longer exposure time, does not show a decrease in cell viability at any concentration of ximelagatran tested, which is in line with results obtained in other hepatic in vitro systems. The mechanism behind the hepatotoxicity of ximelagatran is still unresolved and may involve the action of class II human leukocyte antigens (Kindmark et al., 2008) .
We observe a similar sensitivity for HepG2 cells and hiPS-HEP to the compounds during the acute exposure (48-hour time point). A longer incubation time was not possible to perform using the HepG2 cells due to their high extent of cell proliferation. A comparison with previous studies conducted on PHH indicates a similar ranking of the sensitivity Fig. 2 . Viability curves of hiPS-HEP exposed to compounds for 48 hours (red), 7 days (blue), and 14 days (black), as well as HepG2 exposed to compounds for 48 hours (green). Viability displayed as mean 6 S.E.M. (n = 3). to the tested compounds. PHH seem most sensitive to aflatoxin B1, followed by amiodarone and troglitazone in decreasing order (Gerets et al., 2012; Chatterjee et al., 2014; Szkolnicka et al., 2014) . These studies also demonstrate the large donor-to-donor variability commonly observed with PHH. In addition, the differences in experimental setups and viability readouts complicate the direct comparison of independent studies. Nevertheless, Szkolnicka et al. (2014) reported an extended compound exposure study in PHH over a 7-day time period, in which an increased sensitivity to amiodarone, similar to our results, was detected. However, in contrast to our results, they failed to show a toxic effect for troglitazone during the shorter exposure periods. The general lack of long-term toxicity studies in PHH illustrates the challenges using this model for long-term in vitro culturing.
The hiPS-HEP used in this study have several advantages over existing models in that they are generated in a reproducible way and are possible to cultivate for long periods of time without loss of hepatic phenotype. However, they are also limited by their incomplete expression of some drug-metabolizing enzymes. Intense research is ongoing to improve and refine the differentiation process to generate more mature hPSC-derived hepatocytes. In parallel with these developments and in combination with the possibility of applying prolonged drug exposure times, hPSC-derived hepatocytes are expected to become an important alternative to PHH in future drug discovery and toxicity testing. The pharmaceutical industry will most likely benefit from a predictive cell-based model, with high resemblance to the in vivo situation, which can be used for long-term toxicity assessment. Such a model can potentially be a complement to existing preclinical models, and ultimately allow earlier testing using human relevant tests, resulting in a reduction of the attritions of candidate drugs entering phase II and III clinical trials. Another major advantage with the hPSC-based platform for derivation of functional hepatocytes is the possibility to choose hPSC lines originating from different individuals with diverse genotypes and having the opportunity to assess compound effects on specifically designed panels of hepatocytes derived from a variety of donor lines.
In conclusion, we have performed a to-date, unique long-term chronic toxicity study using hPSC-derived hepatocytes. The cells show a time-dependent toxic response to amiodarone, aflatoxin B1, and troglitazone. On a mechanistic level, we also find specific induction of phospholipidosis and steatosis in the cells. Although the model needs to be challenged with additional toxic compounds, this study demonstrates the utility of hPSC-derived hepatocytes in longterm toxicity assessment and opens up novel avenues for chronic toxicity testing in vitro. 
